Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways

CONCLUSIONS: Anti-EGF VacAbs enhance the antiproliferative effects of drugs targeting the ERK/MAPK and PIK3CA/Akt pathways. Our data provide a rationale for clinical trials testing anti-EGF vaccination combined with inhibitors selected according to the patient's genetic profile.PMID:38183801 | DOI:10.1016/j.tranon.2024.101878

Source: Translational Oncology - January 6, 2024 Category: Cancer & Oncology Authors: Silvia Garc ía-Roman M ónica Garzón-Ibáñez Jordi Bertr án-Alamillo N úria Jordana-Ariza Ana Gim énez-Capitán Beatriz Garc ía-Peláez Marta Vives-Usano Jordi Codony-Servat Erik d'Hondt Rafael Rosell Miguel Ángel Molina-Vila Source Type: research